NAUT Stock Forecast: Nautilus Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.12
−2.30% on the day

The median 12-month analyst price target for Nautilus Biotechnology, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$270.0M
Ticker Nerd rank
70/ 100
Median analyst target
$4.00
Analysts covering
4
Revenue$10K
Operating income−$15.8M
Net income−$14.5M
Free cash flow−$14.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.6%
1M
−16.9%
YTD
+8.7%
1Y
+0.2%
From 52W high
−46.3%
From 52W low
+148.8%
$0.85
$3.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Nautilus Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
70/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
84
Momentum
82
Accruals
69
Issuance
63
Volatility
49
Growth
46
Value
39
Quality
20

Revisions (84): Analysts have, on balance, been raising their forecasts.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NAUT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAUT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26NAUTHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$4.00
Low
$4.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026Roth CapitalInitiatesBuy$3.50
9 Sept 2026Leerink PartnersInitiatesOutperform$4.00
27 Feb 2026GuggenheimMaintainsBuy$2.50 → $4.00
5 Dec 2024Goldman SachsDowngradeSell—
27 June 2024GuggenheimInitiatesBuy—
3 June 2024JefferiesAssumesHold$5.00 → $3.00
3 Aug 2023Morgan StanleyReiteratesEqual-Weight—
3 Aug 2022Goldman SachsMaintainsNeutral—
3 Aug 2022Morgan StanleyMaintainsEqual-Weight—
14 July 2022Goldman SachsMaintainsNeutral—
13 Apr 2022Goldman SachsMaintainsNeutral—
6 Jan 2022Morgan StanleyInitiatesEqual-Weight—
2 Nov 2021Cowen & Co.InitiatesOutperform—
4 Aug 2021Goldman SachsInitiatesNeutral—
13 July 2021JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NAUT.

Market Radar

This page is one stock. Monday covers all of them.

NAUT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NAUT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Nautilus Biotechnology, Inc. returned +0.2% against +6.9% for the S&P 500, dividends included.

NAUT vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26NAUTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NAUT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
636.9×

Cheaper than 1% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−50.0%

Higher than 2% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−41.0%

Higher than 24% of US stocks

Return on assets
−22.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nautilus Biotechnology, Inc. has a market value of $270.0M and an enterprise value of $210.2M.

  • Revenue in the twelve months to 30 June 2026: $10K.

  • Net income over the same four quarters: −$56.5M, a −565210.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.45.

  • Free cash flow in the twelve months to 30 June 2026: −$51.9M.

  • Shares outstanding: 127.2M.

  • Nautilus Biotechnology, Inc. employs 128 people — $78.1 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

NAUT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAUTNautilus Biotechnology, Inc.$270.0M70
GALTGalectin Therapeutics, Inc.$271.3M82
AGENAgenus, Inc.$267.2M82
RLMDRelmada Therapeutics, Inc.$274.8M55
PEPGPepGen Inc.$261.8M53
OCGNOcugen, Inc.$259.9M43
ALTAltimmune, Inc.$258.5M11

Take a look at NAUT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Nautilus Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NAUT

What is the NAUT stock price forecast for 2026-2027?

The median 12-month analyst price target for Nautilus Biotechnology, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAUT stock a buy right now?

Of the 4 analysts covering Nautilus Biotechnology, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nautilus Biotechnology, Inc. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAUT?

As at 21 Nov 2026, Nautilus Biotechnology, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).

Will NAUT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $4, and Ticker Nerd's factor model ranks Nautilus Biotechnology, Inc. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAUT stock forecast for 2030?

No analyst covering Nautilus Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has NAUT stock performed over the past year?

Nautilus Biotechnology, Inc. returned +0.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nautilus Biotechnology, Inc. do?

Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and analysis tools into an integrated workflow.

Company

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and analysis tools into an integrated workflow. Its current products and systems support single-molecule protein analysis and multi-cycle proteome mapping, serving research-oriented markets in biotechnology, pharmaceuticals, and academic science. The company’s platform is intended to help scientists examine protein complexity more deeply, supporting applications in biomedical research, disease biology, and drug discovery. Headquartered in Seattle, Washington, with research and development operations in San Carlos, California, Nautilus Biotechnology operates as a development-stage company in the life sciences tools segment.

CEO Mr. Sujal M. Patel · 128 employees · United States · https://www.nautilus.bio